论文部分内容阅读
目的探讨布地奈德序贯吸入治疗咳嗽变异性哮喘(CVA)的临床疗效及其对患者气道炎性反应的影响。方法选取湖北省中西医结合医院2015—2016年收治的CVA患者90例,随机分为对照组和序贯组,各45例。对照组患者给予布地奈德粉吸入剂治疗,序贯组患者在对照组基础上雾化吸入布地奈德混悬液治疗3 d。两组患者均持续治疗1周。比较两组患者的临床疗效、治疗前后咳嗽症状评分及呼出气一氧化氮(FeNO)值,并观察患者不良反应发生情况。结果治疗前,两组患者咳嗽症状评分及FeNO值比较,差异无统计学意义(P>0.05);治疗后,序贯组患者咳嗽症状评分及FeNO值低于对照组(P<0.05)。两组患者治疗期间均未出现明显不良反应。结论采用布地奈德序贯吸入疗法治疗CVA的临床疗效确切,可有效改善患者临床症状,缓解气道炎性指标,且安全性高。
Objective To investigate the clinical efficacy of sequential inhalation of budesonide in the treatment of cough variant asthma (CVA) and its effect on airway inflammatory response in patients. Methods Ninety patients with CVA who were admitted to Integrative Medicine Hospital of Hubei Province from 2015 to 2016 were randomly divided into control group and sequential group, with 45 cases in each group. Patients in the control group were treated with budesonide inhalation. Patients in the sequential group were treated with inhaled budesonide for 3 days on the basis of the control group. Two groups of patients continued treatment for 1 week. The clinical curative effect, cough symptom score and exhaled gas nitric oxide (FeNO) value before and after treatment were compared between two groups, and the incidence of adverse reactions was observed. Results Before treatment, cough symptom scores and FeNO values were not significantly different between the two groups (P> 0.05). After treatment, the cough symptom scores and FeNO values in the sequential group were lower than those in the control group (P <0.05). No significant adverse reactions occurred in both groups during treatment. Conclusion The clinical efficacy of sequential inhalation of budesonide in the treatment of CVA is clinically effective, which can effectively improve the clinical symptoms and relieve the airway inflammation, and is safe.